<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539301</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0061</org_study_id>
    <nct_id>NCT04539301</nct_id>
  </id_info>
  <brief_title>Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels</brief_title>
  <acronym>UniXa</acronym>
  <official_title>Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite their usefulness in perioperative and acute care settings, factor-Xa&#xD;
      inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The&#xD;
      investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify&#xD;
      the apixaban, rivaroxaban, fondaparinux and danaparoid levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Agreement between measured and estimated levels of each factor-Xa inhibitor</measure>
    <time_frame>2 years</time_frame>
    <description>An estimated anticoagulant level between 80 and 120% of the value obtained by the reference method (&quot;specific assay&quot;) will be deemed clinically acceptable, i.e. the patient's management would have been the same.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the performance of the estimated anticoagulant level method by an inter-laboratory comparison program</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost comparison (estimated anticoagulant level method versus specific dosage)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Anticoagulation</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Derivation cohort</arm_group_label>
    <description>In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:&#xD;
estimated anticoagulant level = conversion factor for this anticoagulant Ã— heparin anti-Xa activity&#xD;
The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Estimated anticoagulant level (conversion factor x anti-Xa activity)</intervention_name>
    <description>Estimated anticoagulant level (conversion factor x anti-Xa activity)</description>
    <arm_group_label>Derivation cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or&#xD;
             fondaparinux&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Patients treated with unfractionated heparin or low molecular weight heparin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elodie BOISSIER</last_name>
    <phone>330240165465</phone>
    <email>elodie.boissier@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annick COULON</last_name>
    <phone>330253482835</phone>
    <email>bp-prom-regl@chu-nantes.fr</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulants (MeSH)</keyword>
  <keyword>Blood Coagulation Tests (MeSH)</keyword>
  <keyword>Drug monitoring (MeSH)</keyword>
  <keyword>Factor Xa Inhibitors (MeSH)</keyword>
  <keyword>Heparin (MeSH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

